Search Results
Your search for ,waY matches 3796 pages
Showing 751 - 800How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care
Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...
Expert Point of View: Johnie Rose, MD, PhD
Invited study discussant, Johnie Rose, MD, PhD, called the correlation between Medicaid expansion and changes in 30-day mortality a critical research question. Dr. Rose is Assistant Professor in the Center for Community Health Integration at Case Western Reserve University School of Medicine and...
Adding Value to Clinical Decision-Making in Nonmetastatic Castration-Resistant Prostate Cancer
Several recent investigations have led to the U.S. Food and Drug Administration (FDA) approval of novel antiandrogens to treat nonmetastatic castration-resistant prostate cancer. Yet, this work has not addressed the treatment of nonmetastatic hormone-sensitive biochemically recurrent prostate...
A Look at Tomorrow’s CAR T-Cell Therapy Today
Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD, of Lu Daopei Hospital, who described the...
Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis...
Active Living After Cancer Program May Improve Physical Functioning for Breast Cancer Survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, reported Tami-Maury et al in the journal Cancer. The results show the program could ...
Breathing Properly May Help You Live Longer
Every system in the body relies on oxygen. From cognition to digestion, effective breathing not only provides us with a greater sense of mental clarity, but it can also help us sleep better, digest food more efficiently, improve our body’s immune response, and reduce stress levels. According to...
Conquer Cancer Updates Mission, Vision; Adopts Values Inspired by Its Donors
To underscore its commitment to scale and grow cancer research funding and to align more closely with ASCO, Conquer Cancer®, the ASCO Foundation, has updated its mission and vision. Mission: Accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Vision: A...
Building a ‘Better Normal’ of Oncology Care to Strengthen Global Health Security After the COVID-19 Pandemic
During the opening session of the 2021 ASCO Annual Meeting, Julio Frenk, MD, PhD, MPH, President of the University of Miami, gave a riveting presentation in which he described the devastating effects of the global COVID-19 pandemic on patients with cancer as well as on fragile and fragmented...
Adoptive Cell Therapy May Soon Be Available for Patients With Melanoma
Oncologists who treat patients with melanoma will need to become familiar with another immunotherapy approach. For refractory metastatic disease, adoptive cell therapy is on the horizon. “Adoptive cell therapy will offer additional hope for our patients with melanoma. We’ll likely be seeing this...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
Overcoming the Disparities in Cancer Survival Among AYA Minority Patients
Although the National Cancer Institute (NCI) has identified adolescents and young adults (AYAs) with cancer as a distinct patient population from children and older adults with the disease, research into the diagnosis, treatment, and survivorship specific to this patient population has not kept...
Integrating Community-Based Interventions Into Cancer Care for Low-Income and Minority Patients May Improve Quality of Life, Reduce Care Disparities
It has been well documented that a confluence of many factors, including low-socioeconomic status, contribute to health disparities and worse outcomes in minority patients with cancer. Strategies that partnered community-based health workers with low-income and minority patients with cancer...
Adjuvant Pembrolizumab for High-Risk Stage II Melanoma: Efficacy and Safety Examined
Adjuvant pembrolizumab reduced the risk of disease recurrence in adults and children aged 12 years and older with high-risk stage II melanoma vs placebo, according to a late-breaking interim analysis of the phase III KEYNOTE-716 trial presented by Jason J. Luke, MD, and colleagues at the European...
Study Examines How Children Cope With a Parent’s Cancer Diagnosis
A cancer diagnosis can abruptly and durably alter the course of daily life—not just for the person diagnosed but also for family members. New research presented by Sinen Korbi, MD, and colleagues at the European Society for Medical Oncology (ESMO) Congress 2021 examined the coping mechanisms of...
Expert Point of View: Carol Aghajanian, MD
“The phase III ENGOT/GCIG study1 proved to be negative, with no advantage seen with the extension of bevacizumab treatment,” said the abstract’s invited discussant, Carol Aghajanian, MD, Chief of the Medical Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, New York. Dr....
Expert Point of View: Surbhi Sidana, MD
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For...
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the ...
COVID-19 Pandemic Spurs Quick Uptick in Telehealth Adoption, ASCO Provides Guidance for Oncologists
ASCO recently released a new set of standards and practice recommendations specific to telehealth in oncology.1 These new standards provide guidance for which patients can be seen through telehealth; the establishment of the doctor-physician relationship; the role of allied health professionals and ...
Lutetium-177–PSMA-617: A First-in-Class Radioligand Therapeutic in Metastatic Prostate Cancer
Based on the findings of the phase III VISION trial, reported by Sartor et al1 and summarized in this issue of The ASCO Post, lutetium-177–PSMA-617 (LuPSMA) is the first of the prostate-specific membrane antigen–targeted cancer theranostics to demonstrate a survival-prolonging benefit for men with...
Improving End-of-Life Discussions With Patients Who Have Advanced Cancer
Although studies have shown that patients with advanced cancer want their oncologists to discuss their advance care plans with them, fewer than half of those patients have that conversation. The reasons are many, including the difficulty many oncologists have in initiating conversations about...
Reduced-Intensity Chemotherapy for Older, Frail Patients With Advanced Gastroesophageal Cancer
Patients who had advanced gastroesophageal cancer but were considered unsuitable for full-dose chemotherapy because of their advanced age and/or frailty “had an improved patient experience with no significant detriment in cancer control” when treated with reduced-intensity chemotherapy in the phase ...
A Scientific Detective Tale With Consequences for the Future of Our Species
With completion of the Human Genome Project, medicine hit a turning point that enabled scientists to approach genetic diseases like cancer with new tools such as disruptive technologies like CRISPR (clustered regularly interspaced short palindromic repeats) gene editing. Progress in this novel...
An Oncologist’s Prescription: Humanity and Love
Cancer care is one of the most technical and scientific of all medical disciplines. Oncologists must keep abreast of a dizzying array of novel treatment options coming out of the laboratory while delivering empathetic care for the physical and emotional needs of their patients with cancer....
How COVID-19 Is Spotlighting the Role of Palliative Medicine
The COVID-19 pandemic has exposed the tragedy of patients dying in isolation, separated from family and friends to limit infection in hospital settings. The process has altered the experience of serious illness for patients and their loved ones, including their ability to grieve, share important...
Gastrointestinal Oncologist Focuses on Both the Art and Science of Treating Patients With Cancer
Chloe Atreya, MD, PhD, was born and reared in Ann Arbor, Michigan. Her mother is a poet, and her father is a planetary physicist and a professor at the University of Michigan. “Some of my early memories that influenced my decision to go into medicine stem from conversations I had with my father...
Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer
A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...
Prostate Cancer Diagnostics: Novel Approaches Are Leaving Conventional Imaging Behind
Advances in molecular imaging are having a big impact on prostate cancer management and outcomes, according to Ashesh B. Jani, MD, the James C. Kennedy Professor in Prostate Cancer, Department of Radiation Oncology at the Winship Cancer Institute of Emory University, Atlanta. Dr. Jani described his ...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care
Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...
Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer
Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...
Report Aims to Assess Contemporary Burden of Brain Tumors in the United States
A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...
ASCO Joins Statement Supporting Mandatory Health Employer COVID-19 Vaccination
With COVID-19 case counts rising amid the spread of the Delta variant, ASCO has joined more than 50 health-care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health-care employers to require their employees to be...
Leland Chung, PhD, Distinguished Mentor and Urologic Oncology Research Scientist, Dies at 80
Talk to anyone who knew Leland Chung, PhD, and you’ll hear the same descriptions of the famed scientist: warm, humble, gracious, brilliant, innovative. Dr. Chung, who served as Director of the Urologic Oncology Research Program at Cedars-Sinai Cancer in Los Angeles for 12 years and was Professor in ...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
Vanderbilt University Appoints Karen Winkfield, MD, PhD, Professor of Radiation Oncology
Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance, and Ingram Professor of Cancer Research, was recently promoted to Professor of Radiation Oncology at Vanderbilt University Medical Center (VUMC). “Grateful to those who paved the way,” said Dr. Winkfield on Twitter, noting...
Early-Phase Study Rediscovers Potential Alternative to Methadone for Cancer Pain
Levorphanol was associated with improved pain and symptom control in patients with advanced cancer, according to data from an early phase I trial, reported by Akhila Reddy, MD, at the 2021 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)...
The Patient We See and the Person We May Not
A middle-aged patient was referred to our clinic with a mass in his liver. It had been detected the preceding year, and the patient underwent a battery of investigations with scans and biopsies to reach a diagnosis of metastatic lesion of the liver. After appropriate consultations with oncologists, ...
RATIONALE 302: Tislelizumab Improves Overall Survival as Second-Line Treatment of Esophageal Cancer
In the phase III RATIONALE 302 trial, the novel anti–PD-1 antibody tislelizumab, being developed in China, improved overall survival vs chemotherapy as second-line therapy for esophageal squamous cell carcinoma, according to Jaffer Ajani, MD, of The University of Houston MD Anderson Cancer Center,...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer “next-generation ...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer...
Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in Nature Cancer. The research...
ASCO/Friends of Cancer Research Joint Position Statement Encourages Enrollment of Patients With Cancer in COVID-19 Vaccine Studies
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a recently released joint position statement. To date, clinical...
Lessons From the Pandemic: How COVID-19 Can Lead to Improvements in Cancer Care
The COVID-19 pandemic may have put the world on pause, but it also showed the medical community that rapid progress is possible with focus and collaboration. During the National Comprehensive Cancer Network (NCCN) Virtual Oncology Policy Summit, “Defining the ‘New Normal’ 2021 and the State of...
Erica Sirrine, PhD, Named Director of Social Work at St. Jude Children’s Research Hospital
Clinical social worker, grief expert, and university dean Erica Sirrine, PhD, has been named Director of Social Work at St. Jude Children’s Research Hospital. For the past 14 years, Dr. Sirrine has worked in higher education, most recently serving as Dean of the College of Behavioral and Social...
Canadian Oncologists Report Costly Delays in Their Drug Regulatory Process
Canada’s publicly funded health-care system has a complex drug approval and funding process. Due to multiple assessment steps and bureaucratic processes, newly developed cancer drugs can often experience long delays before oncologists may use them to treat their patients with cancer. Several...
